Rallybio Corporation

NASDAQ:RLYB

Biotechnology

Healthcare
$15.26 +0.03%

+$0.01 today

Market cap
$82.16M
Beta
-0.88
P/E (TTM)
-11.6
EPS (TTM)
-$1.37
52W Low $2.40High $17.57

Volume 0.03M

Average 0.25M

RLYB Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Rallybio CorporationNASDAQ: RLYB

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash growth accelerates

Q1 FY2026 net change in cash of $9.93M rose 1033.0% year over year, ahead of the +686.5% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash amounted to 2036.2% of revenue in FY2025, up 371.0 pp from a year earlier.
  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1033.0% holds above the trailing-twelve-month pace of +686.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.93M+1426.9% QoQ
Last fiscal yearDec 2025
$17.47M+265.0% YoY
LTMMar 2026
$26.52M+686.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1033.0%——
1 year+265.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
17.47M USD
Year-over-year change
+265.0%
4-year CAGR
-16.0%

Net Change in Cash vs competitors

How RLYB compares with its peers on the latest reported figures

  • RLYB's LTM Mar 2026 net change in cash of $26.52M is the 2nd largest of the 4 companies compared; the peer median is $2.37M.
  • Its year-over-year change of +686.5% is the 2nd highest of 4, against a peer median of +123.6%.
  • Net change in cash amounts to 3090.9% of revenue for RLYB, versus a peer median of 23929.2%.
RLYB Competitors Peer median
Net Change in Cash for RLYB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBIOiBio, Inc.LTM Jun 2026$47.83M +949.1%—47831.0%
RLYBRallybio CorporationLTM Mar 2026$26.52M +686.5%—3090.9%
QTTBQ32 Bio Inc.LTM Mar 2026$14.73M -70.6%—27.4%
BOLDBoundless Bio, Inc.LTM Mar 2026$2.37M +123.6%-28.0%—
Peer median (excluding RLYB) $2.37M+123.6%-28.0%23929.2%

Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47.01M)(66.65M)(74.56M)(57.78M)(8.98M)
Depreciation & Amortization109K167K150K131K92K
Deferred Income Tax00000
Stock-Based Compensation3.65M9.5M10.92M7.99M5.31M
Change in Working Capital(3.78M)(936K)4.28M(258K)(4.19M)
Accounts Receivables00000
Inventory00000
Accounts Payables(976K)487K(99K)(698K)(152K)
Other Working Capital(2.8M)(1.42M)4.38M440K(4.04M)
Other Non-Cash Items1.51M640K(1.05M)627K(22.05M)
Operating Cash Flow(45.53M)(57.28M)(60.27M)(49.28M)(29.81M)
Capital Expenditures(333K)(54K)(12K)00
Acquisitions (Net)(2M)(300K)(2.25M)(2M)0
Purchases of Investments(2M)(201.32M)(110.66M)(48.93M)(17.7M)
Sales of Investments2M89.5M138.33M84.43M46.47M
Other Investing Activities(2K)02.25M018.5M
Investing Cash Flow(2.33M)(112.17M)27.66M33.49M47.27M
Debt Repayment00000
Common Stock Issued86.2M51.53M143K5.41M16K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.23M)(455K)0(206K)0
Financing Cash Flow82.97M51.08M143K5.2M16K
Effect of Forex Changes00000
Net Change in Cash35.1M(118.38M)(32.46M)(10.59M)17.47M
Free Cash Flow(45.87M)(57.34M)(60.28M)(49.28M)(29.81M)

Rallybio Corporation

NASDAQ:RLYB

Intrinsic Alpha fair value

Locked

Current Price

$15.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.